可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 李宏松,刘建平. 冠状动脉支架内血栓形成机制与对策[J]. 心脏杂志, 2008, 20(1):104-107.
[2] 刘普,马依彤. 支架内血栓形成的原因及防治[J]. 心脏杂志, 2008, 20(1):108-110.
[3] 白艳艳,王长谦. 氯吡格雷抵抗研究进展[J]. 心脏杂志, 2007, 19(1):96-98.
[4] Rothlein R, Shen JM, Naser N, et al. TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two A/V shunt models without prolonging bleeding times[J/OL]. Blood(ASH Annual Meeting Abstracts), 2005, 106:1886. http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/1886.
[5] Bauer KA. New anticoagulants: anti IIa vs anti Xa--is one better?[J]. J Thromb Thrombolysis, 2006, 21(1):67-72.
[6] Nagarakanti R, Ezekowitz M, Parcham-Azad K, et al. Long-Term Open Label Extension of the Prevention of Embolic and Thrombotic Events on Dabigatran in Atrial Fibrillation (PETRO- Ex study)[J]. Circulation, 2008, 118:S_922.
[7] Hermans C, Claeys D. Review of the rebound phenomenon in newanticoagulant treatments[J]. Curr Med Res Opin, 2006, 22(3):471-481.
[8] Alexander J. Safety of the factor Xa inhibitor, Apixaban, in combination with antiplatelet therapy after acute coronary syndromes: Results from the APPRAISE-1 dose guiding trial[C/OL]. ESC Congress 2008, Munich Germany, Sep 2, 2008: at ESC. http://www.escardio.org/about/press/press-releases/congress-08/Pages/HotLine3- Alexander-APPRAISE-I.aspx